News

Second-Line Trastuzumab Deruxtecan for Patients With HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma

08/01/2025

Stephanie Holland

According to results from the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan in the second line significantly improved outcomes compared to ramucirumab plus paclitaxel among patients with HER2-positive unresectable or metastatic...

According to results from the...

08/01/2025

Oncology

Conference Coverage

Durvalumab Plus FLOT Improved EFS for Patients With Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

07/03/2025

Allison Casey

According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...

According to the MATTERHORN...

07/03/2025

Oncology

Conference Coverage

Durvalumab Plus FLOT Improved EFS for Patients With Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

07/03/2025

Allison Casey

According to the MATTERHORN...

07/03/2025

Oncology

News

First-Line TFOX Regimen for Patients With HER2-Negative Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

05/02/2025

Stephanie Holland

According to results from the phase 3 PRODIGE 51-FFCD-GASTFOX trial, the TFOX chemotherapy regimen in the first-line setting improved survival and response outcomes compared to FOLFOX among patients with HER2-negative advanced gastric and...

According to results from the...

05/02/2025

Oncology

FDA Approval

FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma

03/19/2025

Stephanie Holland

Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...

Based on results from the...

03/19/2025

Oncology

Videos

Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

02/04/2025

Thierry André, MD

Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.

Thierry Andre, MD, describes...

02/04/2025

Oncology

News

Perioperative Chemotherapy Improves Survival for Patients with Resectable Esophageal Cancer

01/29/2025

Stephanie Holland

According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.

According to results from a...

01/29/2025

Oncology

Xuefeng Leng, MD, PhD, Sichuan Cancer Hospital & Institute

Videos

Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma

01/28/2025

Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.

Xuefeng Leng, MD, explains...

01/28/2025

Oncology

Anna Martling, MD, Karolinska Institutet

Videos

Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations

01/28/2025

Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.

Anna Martling, MD, PhD,...

01/28/2025

Oncology

Conference Coverage

Addition of Evorpacept Shows Promise for Patients With HER2-Positive Gastric or Gastroesophageal Junction Cancer

01/24/2025

Allison Casey

According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.

According to the phase 2...

01/24/2025

Oncology

Recent News

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology